As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Investor's Business Daily on MSN4h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...
7don MSN
We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
One of Europe's most significant strategic assets is the life science industry, which produces cutting-edge drugs and vaccines essential to the ... European Life Science Tools and Reagents Market ...
You can see the complete list of today ... our Earnings ESP Filter. Merck’s top-line growth in the third quarter is likely to have been driven by the cancer drug Keytruda, like in several ...
Following its Q2 results, Merck (MRK) dropped in price below its 200D moving average ... the vast majority of the 200 largest S&P 500 stocks I looked at to compile this list are not in this tricky ...
At its peak, the drug could generate over $6 billion in revenue for Merck. The company also expects ... Rounding out this list of high-yielding stocks is Swiss pharmaceutical giant Novartis ...
Merck & Co has axed two hepatitis drugs in its pipeline ... a deep undercutting of Epclusa’s list price of $74,760 for a 12 week course - and analysts think this move could spark a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback